Skip to main content
Erschienen in: Medical Oncology 9/2021

01.09.2021 | Original Paper

Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method

verfasst von: Shima Shabani, Mehdi Forouzandeh Moghadam, Seyed Latif Mousavi Gargari

Erschienen in: Medical Oncology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Glucose-regulated protein 78 (GRP78) is a well-characterized endoplasmic reticulum (ER) chaperon frequently overexpressed at the surface of tumor cells and associated with tumor survival, metastasis, and chemoresistance. Hence, potential GRP78 binders emerge as promising candidates for cancer therapy and diagnosis. We applied ribosome display to isolate a single-chain variable domain (scFv) specific for the C-terminal domain of a recombinant human GRP78 (CGRP). Six female BALB/c mice were immunized and then splenocyte mRNA was extracted. An scFv-ribosome display library was established by joining the amplified VH/Vκ fragments through a 72-bp linker using overlap extension PCR. Then, selection was performed by applying two rounds of eukaryotic ribosome display panning with stepwise decreased amount of CGRP. Ultimately, the selected scFv was characterized using the indirect-ELISA assay, competitive-ELISA assay, Western blotting, Surface Plasmon Resonance (SPR), and in-silico analyses. The constructed library had a length of ~ 1100 bp and the high-affinity scFvs were isolated using the outputs of the final panning round. Among 60 positive clones, GSF3 was selected and its expression, purification, and binding capacity was confirmed by SDS-PAGE and Western blotting. GSF3 exhibited an affinity of 13 × 107 M−1 to CGRP as assessed by SPR. Moreover, the in-silico analyses indicated that GSF3 binds the C-terminal domain of GRP78 through key residues engaged in antibody-antigen interactions. We found that ribosome display is a swift and reliable technique for specific and high-affinity scFv isolation. Moreover, our results suggest that GSF3 might be applied as a potential cancer immunotherapeutic and diagnostic tool if this approach is carefully followed by successful preclinical and clinical evaluations to validate the findings for further confirmation.
Literatur
1.
Zurück zum Zitat Yang YF, et al. Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling. J Inflamm Res. 2021;14:1217–33.CrossRef Yang YF, et al. Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling. J Inflamm Res. 2021;14:1217–33.CrossRef
2.
Zurück zum Zitat Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89–102.CrossRef Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89–102.CrossRef
3.
Zurück zum Zitat Lu G, Luo H, Zhu X. Targeting the GRP78 pathway for cancer therapy. Front Med (Lausanne). 2020;7:351.CrossRef Lu G, Luo H, Zhu X. Targeting the GRP78 pathway for cancer therapy. Front Med (Lausanne). 2020;7:351.CrossRef
4.
Zurück zum Zitat Gopal U, Pizzo SV. Cell surface GRP78 signaling: an emerging role as a transcriptional modulator in cancer. J Cell Physiol. 2021;236(4):2352–63.CrossRef Gopal U, Pizzo SV. Cell surface GRP78 signaling: an emerging role as a transcriptional modulator in cancer. J Cell Physiol. 2021;236(4):2352–63.CrossRef
5.
Zurück zum Zitat Misra UK, et al. Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. Mol Cancer Ther. 2009;8(5):1350–62.CrossRef Misra UK, et al. Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. Mol Cancer Ther. 2009;8(5):1350–62.CrossRef
6.
Zurück zum Zitat Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451–61.CrossRef Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451–61.CrossRef
7.
Zurück zum Zitat Ahmad ZA, et al. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.CrossRef Ahmad ZA, et al. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.CrossRef
8.
Zurück zum Zitat Li R, et al. Ribosome display: a potent display technology used for selecting and evolving specific binders with desired properties. Mol Biotechnol. 2019;61(1):60–71.CrossRef Li R, et al. Ribosome display: a potent display technology used for selecting and evolving specific binders with desired properties. Mol Biotechnol. 2019;61(1):60–71.CrossRef
9.
Zurück zum Zitat Hanes J, et al. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci U S A. 1998;95(24):14130–5.CrossRef Hanes J, et al. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci U S A. 1998;95(24):14130–5.CrossRef
10.
Zurück zum Zitat Schaffitzel C, et al. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods. 1999;231(1–2):119–35.CrossRef Schaffitzel C, et al. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods. 1999;231(1–2):119–35.CrossRef
11.
Zurück zum Zitat He M, et al. Selection of a human anti-progesterone antibody fragment from a transgenic mouse library by ARM ribosome display. J Immunol Methods. 1999;231(1–2):105–17.CrossRef He M, et al. Selection of a human anti-progesterone antibody fragment from a transgenic mouse library by ARM ribosome display. J Immunol Methods. 1999;231(1–2):105–17.CrossRef
12.
Zurück zum Zitat Mattheakis LC, Bhatt RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci U S A. 1994;91(19):9022–6.CrossRef Mattheakis LC, Bhatt RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci U S A. 1994;91(19):9022–6.CrossRef
13.
Zurück zum Zitat Salimi F, Moghadam MF, Rajabibazl M. Development of a anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B. Mol Biol Rep 2018;45(6)2247–56. Salimi F, Moghadam MF, Rajabibazl M. Development of a anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B. Mol Biol Rep 2018;45(6)2247–56.
14.
Zurück zum Zitat Yau KY, et al. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J Immunol Methods. 2003;281(1–2):161–75.CrossRef Yau KY, et al. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J Immunol Methods. 2003;281(1–2):161–75.CrossRef
15.
Zurück zum Zitat Lee MS, et al. Selection of scFvs specific for HBV DNA polymerase using ribosome display. J Immunol Methods. 2004;284(1–2):147–57.CrossRef Lee MS, et al. Selection of scFvs specific for HBV DNA polymerase using ribosome display. J Immunol Methods. 2004;284(1–2):147–57.CrossRef
16.
Zurück zum Zitat Stefan N, et al. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol. 2011;413(4):826–43.CrossRef Stefan N, et al. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol. 2011;413(4):826–43.CrossRef
17.
Zurück zum Zitat Zahnd C, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol. 2007;369(4):1015–28.CrossRef Zahnd C, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol. 2007;369(4):1015–28.CrossRef
18.
Zurück zum Zitat Mala J, et al. Construction and sequencing analysis of scFv antibody fragment derived from monoclonal antibody against norfloxacin (Nor155). J Genet Eng Biotechnol. 2017;15(1):69–76.CrossRef Mala J, et al. Construction and sequencing analysis of scFv antibody fragment derived from monoclonal antibody against norfloxacin (Nor155). J Genet Eng Biotechnol. 2017;15(1):69–76.CrossRef
19.
Zurück zum Zitat Nian S, et al. Development and identification of fully human scFv-Fcs against Staphylococcus aureus. BMC Immunol. 2016;17(1):8.CrossRef Nian S, et al. Development and identification of fully human scFv-Fcs against Staphylococcus aureus. BMC Immunol. 2016;17(1):8.CrossRef
20.
Zurück zum Zitat Aghamollaei H, et al. Structure prediction, expression, and antigenicity of c-terminal of GRP78. Biotechnol Appl Biochem. 2017;64(1):117–25.CrossRef Aghamollaei H, et al. Structure prediction, expression, and antigenicity of c-terminal of GRP78. Biotechnol Appl Biochem. 2017;64(1):117–25.CrossRef
21.
Zurück zum Zitat Luo Y, Xia Y. Selection of single-chain variable fragment antibodies against fenitrothion by ribosome display. Anal Biochem. 2012;421(1):130–7.CrossRef Luo Y, Xia Y. Selection of single-chain variable fragment antibodies against fenitrothion by ribosome display. Anal Biochem. 2012;421(1):130–7.CrossRef
22.
Zurück zum Zitat Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987;100(1–2):173–9.CrossRef Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987;100(1–2):173–9.CrossRef
23.
Zurück zum Zitat Schasfoort RB, editor. Handbook of surface plasmon resonance. Royal Society of Chemistry; 2017. Schasfoort RB, editor. Handbook of surface plasmon resonance. Royal Society of Chemistry; 2017.
24.
Zurück zum Zitat Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized VJ and VDJ sequence analysis. Nucleic Acids Res. 2008;36(suppl_2):W503–8. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized VJ and VDJ sequence analysis. Nucleic Acids Res. 2008;36(suppl_2):W503–8.
25.
Zurück zum Zitat Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the robetta server. Nucleic Acids Res. 2004;32(suppl_2):W526–31.CrossRef Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the robetta server. Nucleic Acids Res. 2004;32(suppl_2):W526–31.CrossRef
26.
Zurück zum Zitat Ko J, et al. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012;40:W294–7.CrossRef Ko J, et al. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012;40:W294–7.CrossRef
27.
Zurück zum Zitat Comeau SR, et al. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004;32:W96–9.CrossRef Comeau SR, et al. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004;32:W96–9.CrossRef
28.
Zurück zum Zitat DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsletter on protein crystallography. 2002;40(1):82–92. DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsletter on protein crystallography. 2002;40(1):82–92.
29.
Zurück zum Zitat Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–86.CrossRef Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–86.CrossRef
30.
Zurück zum Zitat Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8(2):127–34.CrossRef Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8(2):127–34.CrossRef
31.
Zurück zum Zitat Swift ML. GraphPad prism, data analysis, and scientific graphing. J Chem Inf Comput Sci. 1997;37(2):411–2.CrossRef Swift ML. GraphPad prism, data analysis, and scientific graphing. J Chem Inf Comput Sci. 1997;37(2):411–2.CrossRef
32.
Zurück zum Zitat Elfiky AA, et al. GRP78 targeting: hitting two birds with a stone. Life Sci. 2020;260:118317.CrossRef Elfiky AA, et al. GRP78 targeting: hitting two birds with a stone. Life Sci. 2020;260:118317.CrossRef
33.
Zurück zum Zitat Liu R, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res. 2013;19(24):6802–11.CrossRef Liu R, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res. 2013;19(24):6802–11.CrossRef
34.
Zurück zum Zitat Rasche L, et al. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 2015;100(3):377–84.CrossRef Rasche L, et al. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 2015;100(3):377–84.CrossRef
35.
Zurück zum Zitat Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–38. Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–38.
36.
Zurück zum Zitat He M, Khan F. Ribosome display: next-generation display technologies for production of antibodies in vitro. Expert Rev Proteomics. 2005;2(3):421–30.CrossRef He M, Khan F. Ribosome display: next-generation display technologies for production of antibodies in vitro. Expert Rev Proteomics. 2005;2(3):421–30.CrossRef
37.
Zurück zum Zitat Liu L, Xu W. Targeting nitric oxide mediated upregulation of membrane-bound glucose regulated-protein 78 by subtractive single chain Variable Fragment (scFv) phage display. Am J Biomed Sci. 2009;1(4):321–35.CrossRef Liu L, Xu W. Targeting nitric oxide mediated upregulation of membrane-bound glucose regulated-protein 78 by subtractive single chain Variable Fragment (scFv) phage display. Am J Biomed Sci. 2009;1(4):321–35.CrossRef
38.
Zurück zum Zitat Gill P, inventors. Antibodies that bind cell surface grp78 and their use for detection of cancer. United States patent application US 15/590,379; 2018. Gill P, inventors. Antibodies that bind cell surface grp78 and their use for detection of cancer. United States patent application US 15/590,379; 2018.
39.
Zurück zum Zitat de Ridder GG, Ray R, Pizzo SV. A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. Melanoma Res. 2012;22(3):225–35.CrossRef de Ridder GG, Ray R, Pizzo SV. A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. Melanoma Res. 2012;22(3):225–35.CrossRef
40.
Zurück zum Zitat Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155–61.CrossRef Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155–61.CrossRef
41.
Zurück zum Zitat Adams GP, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750–5.PubMed Adams GP, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750–5.PubMed
42.
Zurück zum Zitat Kabat EA, Wu T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol. 1991;147(5):1709–19.PubMed Kabat EA, Wu T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol. 1991;147(5):1709–19.PubMed
Metadaten
Titel
Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method
verfasst von
Shima Shabani
Mehdi Forouzandeh Moghadam
Seyed Latif Mousavi Gargari
Publikationsdatum
01.09.2021
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 9/2021
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-021-01561-3

Weitere Artikel der Ausgabe 9/2021

Medical Oncology 9/2021 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.